Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 04, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,400.9701 pence per share.
- Treasury Shares Held: 283,042,678 shares following the transaction.
- Shares in Issue: 5,727,560,413 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 500,000 shares for Treasury. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of Treasury shares held (283,042,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total voting rights denominator (5,727,560,413) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Note that this document does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.